Wind River Studio Enabling Hyundai Mobis and Hyundai AutoEver to Accelerate Development of Next-Gen Intelligent and Connected Vehicles
3.5.2022 13:00:00 EEST | Business Wire | Press release
Wind River®, a global leader in delivering software for mission-critical intelligent systems, today announced that Hyundai Mobis, one of the world’s largest vehicle technology innovators and suppliers, and Hyundai AutoEver has signed an agreement to establish a strategic relationship that includes collaboration with Wind River Studio for the development of an automotive software framework and continuous test and test automation capabilities, as well as advanced software lifecycle management.
“As we move toward a more connected and autonomous future, software is at the center of enabling that reality,” said Avijit Sinha, chief product officer, Wind River. “Wind River Studio can help automotive leaders such as Hyundai Mobis and Hyundai AutoEver achieve a modernized development framework across cloud and edge, combined with software lifecycle management capability to enable them to accelerate their innovation and advance the software defined vehicle.”
“Hyundai Mobis plans to continue to introduce new services by adding future mobility technology to intelligent vehicles through extensive cooperation,” said Chang Jae-ho, senior vice president at Hyundai Mobis.
“Hyundai AutoEver plays the role of software specialist in the Hyundai Motor Group and is leading the team towards digital transformation to revolutionize software development and verification processes throughout vehicle development,” said Kim Seong-woon, vice president, head of the Software Quality Innovation Division at Hyundai AutoEver. “Through close cooperation with Wind River, we will strengthen the function and efficiency of Hyundai AutoEver’s software integrated development environment platform and virtual verification platform to contribute to innovation in vehicle software development by Hyundai Mobis and group companies.”
The auto industry is amid its most significant revolution in more than 100 years. Research from Forbes indicates that automotive leaders believe an intelligent systems approach is central to strategies that can deliver up to a 30% growth in revenue opportunities, and in five years’ time, many of the core requirements for intelligent systems in this industry will need to be in place.1
The collaboration will leverage each company’s specialties and experiences to develop a best-in-class software development infrastructure for next-generation connected automobiles. The companies will work closely on methodologies to accelerate the development and delivery of automotive systems, including enhanced continuous test capabilities and test automation in both simulated and real hardware-based environments and new customer test infrastructures making use of virtual device management.
The Hyundai AutoEver team will play a key role working with Wind River on a software integrated development environment platform and virtual verification platform.
Studio provides a cloud-native platform for the development, deployment, operations, and servicing of mission-critical intelligent systems. Studio delivers a full lifecycle management platform for intelligent systems at cloud scale. Studio enables development workflows that reduce development costs and accelerate capabilities for building, testing, and deploying on the edge.
More information about Wind River Studio is available at www.windriver.com/studio.
About Wind River
Wind River is a global leader in delivering software for mission-critical intelligent systems. For 40 years, the company has been an innovator and pioneer, powering billions of devices and systems that require the highest levels of security, safety, and reliability. Wind River software and expertise are accelerating digital transformation across industries, including automotive, aerospace, defense, industrial, medical, and telecommunications. The company offers a comprehensive portfolio supported by world-class professional services and support and a broad partner ecosystem. To learn more, visit Wind River at www.windriver.com.
About Hyundai MOBIS
Hyundai Mobis is the no.7 global automotive supplier, with annual sales of nearly $30 billion USD. The company was founded in 1977 and is headquartered in Seoul, Korea. Hyundai Mobis aims to become a lifelong technology partner for vehicles and people. The company has outstanding expertise in sensors, sensor fusion in ECUs and software development for safety control. The company’s products also include various components for electrification, brakes, chassis and suspension, steering, airbags, lighting, and automotive electronics.
About Hyundai AutoEver
Hyundai AutoEver, a mobility software provider that reliably, efficiently, and innovatively supports software and infrastructure across in-car and out-car areas, builds a mobility software platform to flexibly connect hardware and software, and is creating new value for the upcoming mobility ecosystem.
1 Forbes/Wind River, “Characteristics of Intelligent Systems,” 2021
Wind River is a trademark or registered trademark of Wind River Systems, Inc., and its affiliates. Other names may be the trademarks of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220503005428/en/
Contact information
Jenny Suh
Wind River
510-749-2972
jenny.suh@windriver.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom